Royalty Pharma Sub-Manager
New York, NYfiles as Royalty Pharma Sub-Manager, LLC
$242m in 4 US stocks at the end of 30 June 2026. The top 10 are 100.0% of the money. It changed about 26.0% of the portfolio this quarter.
Value
$242m
Stocks
4
Top 10 share
100.0%
Turnover
26.0%
What changed this quarter
New
Bought for the first time this quarter.
- Kailera TherapeuticsKLRA22.4% of the fund
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
Holdings
- Kailera TherapeuticsKLRA
- Share
- 22.4%
- Value
- $54m
- Shares
- 2,455,357
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| CytokineticsCYTK | 34.5% | $84m | 980,392 | Held |
| Zenas BioPharmaZBIO | 25.1% | $61m | 2,388,150 | Held |
| Kailera TherapeuticsKLRA | 22.4% | $54m | 2,455,357 | New |
| BiohavenBHVN | 18.1% | $44m | 2,936,507 | Held |
Over time and by industry
Value over time
Dec '25
Jun '26
Value is up 41.2% since 31 December 2025.
Where the money is
Health care100.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.